ANTIBACTERIAL THERAPY OF PATIENTS WITH CHRONIC PROSTATITIS: FINDING A WAY OUT OF THERAPEUTIC «DEADLOCK»


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatment of patients with chronic prostatitis is one of the most urgent problems of modern urology. According to most of the existing recommendations, fluoroquinolones are the drugs of choice in treatment of prostatitis. Recently, however, many researchers have noted the increasing role of intracellular pathogens, and high activity of macrolides and tetracyclines against these pathogens. This article provides an overview of the literature on recommended and promising antibiotics used in the treatment of patients with chronic prostatitis.

Full Text

Restricted Access

About the authors

G. A Voskanyan

First MSMU n.a. I.M. Sechenov

Email: albert.voskanyan@gmaiI.com
postgraduate student at the Department of Urology

A. Z Vinarov

First MSMU n.a. I.M. Sechenov; SRI of Uronephrology and Reproductive Human Health

References

  1. McNaughton Collins M., Meigs J.B., Barry M.J. et al. Prevalence and correlates of prostatitis in the health professionals followup study cohort. J Urol. 2002; 167: 1363-1366.
  2. Collins M.M., Stafford R.S., O'Leary M.P. et al. How common isprostatitis? A national survey of physician visits. J Urol. 1998; 159:1224-1228.
  3. Nickel J. C., Downey J, Hunter D. et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001;165:842-845.
  4. Roberts R.O., Lieber M.M., Rhodes T. et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urolog.y 1998; 51:578-584.
  5. Krieger J.N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol. Nefrol. 2004; 56:99-107.
  6. McNaughton Collins M., Pontari M.A., O'Leary M.P. et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen. Intern. Med. 2001; 16:656-662.
  7. Workshop Committee of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Chronic Prostatitis Workshop, Bethesda, MD, 7-8 December 1995.
  8. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest. Urol. 1968;5:492-518.
  9. Weidner W., Schiefer H.G., Krauss H. et al. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991;19(Suppl. 3):S119-125.
  10. Cohen J.M., Fagin A.P., Hariton E. et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One. 2012;7(8):e41941.
  11. Weidner W., Diemer Th, Huwe P. et al. The role of Chlamydia trachomatis in prostatitis. Int. J Antimicrob. Agents. 2002;19:466-470.
  12. Nickel J.C., Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. Urology. 2005;66:2-8.
  13. Johnson J.R., Drawz S.M., Porter S. et al. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob. Agents Chemother. 2013;57(10):4856-4860.
  14. Johnson L., Sabel A., Burman W.J. et al. Emergence of fluoroquinone resistance in outpatient urinary Escherichia coli isolates. Am. J Med. 2008;121:876-884.
  15. Feliciano J., Teper E., Ferrandino M. et al. The incidence of fluoroquinolone resistant infections after prostate biopsy - arefluoroquinolones still effective prophylaxis? J Urol. 2008;179:952-955.
  16. Палагин И.С., Сухорукова М.В., Дехнич А.В. и др. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010-2011). Клин. Микробиол. Антимикроб. Химиотер. 2012; 14(4):280-302.
  17. Lipsky B.A., Byren I., Hoey C. T. Treatment of bacterial prostatitis. Clin. Infect Dis. 2010;50(12):1641-1652.
  18. Johnson J.R., Kuskowski M.A., Gajewski A. et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect. Dis. 2005;191:46-50.
  19. Nickel J.C., Olson M.E., Barabas A. et al. Pathogenesis of chronic bacterial prostatitis in an animal model. Br. J Urol. 1990;66:47-54.
  20. Charalabopoulos K., Karachalios G., Baltogiannis D. et al. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003;49:269-279.
  21. Wagenlehner F.M., Weidner W., Sorgel F. et al. The role of antibiotics in chronic bacterial prostatitis. Int. J Antimicrob. Agents. 2005;26:1-7.
  22. Nickel J. C., Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol. 2008;179:1391-1395.
  23. Wise G.J., Shteynshlyuger A. Atypical infections of the prostate. Curr. Prostate Rep. 2008;6:86-93.
  24. Jones R.B. Chlamydia trachomatis (trachoma, perinatal infections, lymphogranulomavenereum and other genital infections). In: Mandell G.L, Bennett J.E, Dolin R.E, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Living-stone, 2000.
  25. Schachter J. Chlamydia trachomatis infections: epidemiology and disease spectrum. In: Oriel J.D, Harris J.R.W, editors. Sexually transmitted diseases. Edinburg: Churchill Livingstone, 1986:39/58.
  26. Skerk V., Schönwald S., Krhen I. et al. Aetiology of chronic prostatitis. Int. J Antimicrob. Agents. 2002;19(6):471-474.
  27. Skerk V., Krhen I., Schonwald S. et al. The role of unusual pathogens in prostatitis syndrome. Int. J Antimicrob. Agents. 2004;24(Suppl. 1):S53-56.
  28. Skerk V., Marekovic I., Markovinovic L. et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasmaurealyticum. Chemotherapy. 2006;52(1):9-11.
  29. Schaeffer A.J., Knauss J.S., Landis J.R. et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol. 2002; 168:1048-1053.
  30. Weidner W., Diemer Th., Huwe P. et al. The role of Chlamydia trachomatis in prostatitis. Int. J Antimicrob. Agents. 2002;19:466-470.
  31. Badalyan R.R., Fanarjyan S.V., Aghajanyan I.G. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia. 2003;35(5):263-265.
  32. Xiao J.L., Ren L., Lv H. et al. Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a case-control study. Urol. Int. 2013;91(4):410-16.
  33. Choi Y.S., Kim K.S., Choi S.W. et al. Microbiological etiology of bacterial prostatitis in general hospital and primary care clinic in Korea. Prostate Int. 2013; 1(3):133-138.
  34. Nassar F.A., Abu-Elamreen F.H., Shubair M.E. et al. Detection of Chlamydia trachomatis and Mycoplasma hominis, genitalium and Ureaplasmaurealyticum by polymerase chain reaction in patients with sterile pyuria. Adv. Med. Sci. 2008;53(1):80-86.
  35. Винаров А.З., Аляев Ю.Г., Фиев Д.Н. и др. Микоплазменная инфекция предстательной железы и ее возможная роль в патогенезе рака простаты. Андрология и генитальная хирургия. 2009;4:18-22.
  36. Barykova Y.A., Logunov D.Yu., Shmarov M.M. et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget. 2011 ;l2(4):289-297.
  37. Skerk V., Krhen I., Cajic V. et al. The role of Chlamydia trachomatis in prostatitis syndrome - our experience in diagnosis and treatment. Acta Dermatovenerol. Croat. 2007;15(3):135-40.
  38. Vicari E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection. Hum Reprod. 2000;15(12):2536-2544.
  39. Lin H.P., Lu H.X. Analysis of detection and antimicrobial resistance of pathogens in prostatic secretion from 1186 infertile men with chronic prostatitis. Zhonghua Nan KeXue. 2007; 13(7):628-631.
  40. Yan Z.H., Zhou M., Zhang W. et al. Prevalence and drug tolerance of mycoplasma in patients with urogenital inflammation Zhonghua Nan KeXue. 2003; 9(8):599-600, 603.
  41. Magri V., Trinchieri A., Ceriani I. et al. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. Arch. Ital. Urol. Androl. 2007;79(2):93-98.
  42. Grabe M., Bjerklund-Johansen T.E., Botto H. et al. 2013 EAU Guidelines on Urological Infections.
  43. Magri V., Montanari E., Skerk V. et al. Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian. J Androl. 2011; 13(6): 819-827.
  44. Skerk V. Azithromycin in the treatment of chronic bacterial prostatitis20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, April 10-13, 2010. ClinMicrobiol Infect 2010. 16S42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies